Page 54 - MEMORIA ANUAL 2018 SEHH-FEHH

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2018
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
M. Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexametha- sone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood. 2018;132:3245. doi: https://doi.org/10.1182/blood-2018-99-112659. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Mateos MV, Martínez López J, Rodríguez-Otero P, Ocio EM, González MS, Oriol A, Gutiérrez N, Paiva B, Ríos R, Rosiñol L, Álvarez MA, Calasanz MJ, Bargay J, González AP, Escalante F, Martínez R, Puig N, de la Rubia J, Teruel AI, Cedena MT, De Arriba F, Palomera L, Hernández MT, López Jiménez J, Martín J, Piensa E, García-Mateo A, González V, Bladé J, Lahuerta JJ, San Miguel JF. Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood. 2018;132:2142. doi: https://doi.org/10.1182/blood-2018-99-112656. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Goicoechea I, Puig N, Cedena MT, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Gutiérrez NC, Calasanz MJ, Martín-Ramos ML, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodríguez I, Sarvide S, García-Sanz R, Martínez- López J, Oriol A, Ríos R, Martín J, Martínez R, Sarra J, Hernández MT, De La Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Bladé J, San-Miguel JF, Paiva B. Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. Blood. 2018;132:112. doi: https://doi.org/10.1182/ blood-2018-99-113312. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Jiménez Ubieto A, Martínez López J, Rosiñol L, Paiva B, Cedena MT, Puig N, Calasanz MJ, González Medina J, Martín-Ramos ML, Alonso Fernández RA, Oriol A, Blanchard J, Ocio EM, De La Rubia J, Ríos R, Martín J, Hernández MT, Krsnik I, Moraleda JM, Palomera L, Bargay J, Mateos MV, San-Miguel JF, Bladé J, Lahuerta JJ. Absence of Con- tribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Con- ventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood. 2018;132:1943. doi: https://doi.org/10.1182/blood-2018-99-116604. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Ottmann OG, Pfeifer H, Cayuela JM, Spiekermann K, Jung W, Beck J, Raffoux E, Turlure P, Himberlin C, Huguet F, Viardot A, Wendelin K, Reichle A, Maury S, Sanhes L, Isnard F, Cahn JY, Lepretre S, Chevallier P, Escoffre-Barbe M, Ribera JM, Hoelzer D, Goekbuget N, Dombret H, Rousselot P. Nilotinib (Tasigna®) and Low Intensity Chemo- therapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). Blood. 2018;132:31. doi: https://doi.org/10.1182/ blood-2018-99-114552. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cade- nas I, Vives S, Ribera J, González-Campos J, Díaz-Beyá M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Bergua JM, Calbacho M, Hernández-Rivas JM, Monsalvo S, Novo A, Cervera M, García-Guiñón A, Junca J, Ciudad J, Orfao A, Ribera JM. Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols. Blood. 2018;132:1553. doi: https://doi. org/10.1182/blood-2018-99-114559. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
• Ballesteros J, Martínez-Cuadrón D, Martínez López J, Bergua Burgués JM, Tormo M, Serrano J, González A, Pérez De Oteyza J, Vives S, Vidriales MB, Herrera P, Vera JA, López Martínez A, de la Fuente A, Amador Barciela L, Hernández-Ri- vas JA, Fernández Fernández MA, Cervero C, Morillo D, Hernández P, Primo D, Gorrochategui J, Rojas JL, Troconiz I, Villoria J, Sanz M, Montesinos P. Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments. Blood. 2018;132:1493. doi: https://doi. org/10.1182/blood-2018-99-115849. 60th ASH Annual Meeting and Exposition. San Diego, 1-4 de diciembre de 2018.
54